Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 25 - 26, 2026!

For more Information and Register: Delaware ACC By the Sea: 2026 Chapter Meeting

Download the Brochure: Brochure

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

AI in CV Diagnosis: From Smartwatch Screening to Faster Echo Interpretation
Two late-breaking studies presented at AHA 2026 highlight AI's potential to extend cardiovascular screening and improve diagnostic workflow, while underscoring the continued importance of clinician oversight.
ATTAIN-OSA: Orforglipron For Severe OSA in Adults With Obesity or Overweight
Once-daily oral orforglipron improved moderate to severe obstructive sleep apnea (OSA) compared with placebo in adults with obesity or overweight, based on findings from the ATTAIN-OSA trial presented at AHA 2026 and simultaneously published in JAMA.
NCDR Research at AHA 2026: OAC After LAAO; PCI and tMCS in Patients With Ischemic Cardiomyopathy
Explore key findings from two AHA 2026 abstracts using NCDR registry data.
TYDAL-TIMI 78: ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglyceride Levels
Inhibition of angiopoietin-like protein 4 (ANGPTL4) with the monoclonal antibody MAR001 significantly reduced fasting triglyceride levels at 12 weeks, based on findings from the TYDAL-TIMI 78 trial presented at AHA 2026 and simultaneously published in NEJM.
Online Exclusive | From the Member Sections | Integrating Palliative Care Into LVAD Care
Caring for a person with a left ventricular assist device (LVAD) teaches the importance of shared decision-making and the complexities of care through the end of life. Clinicians carry those memories, such as a young mother living with an LVAD and recurrent driveline infections...